Phaseline

Companies › Cardurion Pharmaceuticals

Cardurion Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Cardiovascular; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CRD-4730
Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibitor
CAMK2A, CAMK2B, CAMK2D, CAMK2GPhase 2Catecholaminergic Polymorphic Ventricular Tachycardia; Heart Failure With Reduced Ejection Fraction (HFrEF)Apr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06658899CRD-4730Phase 2Catecholaminergic Polymorphic Ventricular TachycardiaCardiovascularApr 2027
NCT07750873CRD-4730Phase 2Heart Failure With Reduced Ejection Fraction (HFrEF)CardiovascularSep 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CAMK2A (1) CAMK2B (1) CAMK2D (1) CAMK2G (1)

Companies with the same targets

–

Companies built like this

Nyrada AllRock Bio Zomagen Biosciences Agiana Pharmaceuticals Research Institute of Geroprotective Technologies

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.